Loading
Protein Degradation and Inhibitors / Mechanisms of Cancer Metastasis · Journal article
Biomarker Research · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing expanded VHL-targeted therapeutic strategies beyond the canonical HIF-2α axis, including small-molecule inhibitors and PROTACs targeting non-HIF VHL substrates in ccRCC and pan-cancer contexts. The evidence base is predominantly preclinical (cell-line and xenograft models), and the authors explicitly acknowledge that realizing clinical potential requires resolution of key unresolved questions regarding substrate directness, tissue tropism, and resistance mechanisms.
Journal article. Patients with VHL-deficient clear cell renal cell carcinoma (ccRCC) and VHL-proficient malignancies across pan-cancer contexts (addressed conceptually, not studied empirically in this review)..
VHL encodes the core substrate-recognition subunit of the Cullin2-RING E3 ubiquitin ligase complex, regulating cellular oxygen sensing and proteostasis. Targeting the canonical VHL-HIF axis (e.g., belzutifan) has improved advanced ccRCC management, but intrinsic non-responsiveness and acquired resistance to HIF-2α inhibitors present major clinical limitations. Non-canonical VHL targets span epigenetic regulation (ZHX2, SETDB1, METTL3/METTL14), metabolic reprogramming (NDRG3, TFAM), extracellular matrix architecture (fibronectin, COL4A2), and immune modulation (TBK1).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies promising mechanistic targets and therapeutic modalities (small-molecule inhibitors and PROTACs) for overcoming HIF-2α inhibitor resistance in ccRCC. However, clinicians should recognize that all supporting evidence is preclinical; no human clinical trial data are presented, and key pharmacological and mechanistic questions remain unresolved.
A narrative review synthesizing preclinical mechanistic evidence on VHL targets and proposing therapeutic modalities, lacking clinical trial data or human evidence to support practice recommendations.
This review identifies promising mechanistic targets and therapeutic modalities (small-molecule inhibitors and PROTACs) for overcoming HIF-2α inhibitor resistance in ccRCC. However, clinicians should recognize that all supporting evidence is preclinical; no human clinical trial data are presented, and key pharmacological and mechanistic questions remain unresolved.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The von Hippel-Lindau ( VHL ) gene encodes the core substrate-recognition subunit of the Cullin2-RING E3 ubiquitin ligase complex, regulating cellular oxygen sensing and proteostasis. While targeting the canonical VHL-hypoxia-inducible factor (HIF) axis (e.g. belzutifan) has improved advanced clear cell renal cell carcinoma (ccRCC) management, intrinsic non-responsiveness and acquired resistance to HIF-2α inhibitors present major clinical limitations. Expanding beyond the HIF-centric paradigm reveals a broader network of non-canonical VHL targets, offering new opportunities for therapeutic development across ccRCC and pan-cancer contexts. This review provides an evidence-graded synthesis of novel VHL targets spanning epigenetic regulation (e.g. ZHX2, SETDB1, METTL3/METTL14), metabolic reprogramming (e.g. NDRG3, TFAM), extracellular matrix architecture (e.g. fibronectin, COL4A2), and immune modulation (e.g. TBK1). Supporting evidence across these targets ranges from direct biochemical ubiquitination to indirect downstream observations, derived predominantly from preclinical cell-line and xenograft models. Disruption of VHL and these non-HIF networks contributes to oncogenesis across diverse malignancies. Translating these mechanistic insights catalyzes two distinct therapeutic modalities. For VHL -deficient malignancies, selectively intercepting unshielded downstream effectors with small-molecule inhibitors provides rational, vulnerability-targeted salvage strategies. Conversely, in VHL -proficient malignancies, the exceptional chemical tractability of VHL has been repurposed by proteolysis targeting chimeras (PROTACs). VHL-recruiting PROTACs hijack operational ligase machinery to degrade targeted oncogenic drivers, including some previously “undruggable” oncogenes. These next-generation degraders offer potential biomarker-driven strategies to overcome current therapeutic bottlenecks in ccRCC and other associated malignancies. However, current evidence derives predominantly from in vitro and animal models. Realizing the clinical potential of VHL-targeted strategies requires addressing key unresolved questions regarding substrate directness, tissue tropism, and resistance trade-offs. Further investigating these core mechanistic and pharmacological bottlenecks will be essential to guide next-generation therapies in VHL-associated malignancies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.